Analysis of Pharmocovigilance and Difference with the ADR Monitoring in China

Abstract

Abstract: Objective To explore the application of pharmacovigilance in China. Methods The concept of parmocovigilance and the differences between pharmacovigilance and ADR Monitoring were disserted. Results There is a gap between ADR monitoring and pharmacovigilance in the aspect of object, scope and method. However, ADR monitoring is in keeping with international pharmacovigilance theoretically and is developing towards it. Conclusion Pharmacovigilancecan provide growth space for development of ADR monitoring in china.

Key words: parmocovigilance, ADR monitoring, analysis, difference

CLC Number:

WANG Dan, PENG Li-li, LIU Cui-li, LIU Jia, WANG Tao, DONG Duo. Analysis of Pharmocovigilance and Difference with the ADR Monitoring in China[J]. Chinese Journal of Pharmacovigilance, 2017, 14(3): 150-152.

References

[1] 施文.各国药物不良反应监测的发展和现状[N].医药经济报,2002-8-9(6).
[2] Springer Vienna. WHO collaborating centre for international drug monitoring [M].Dictionary of Pharmaceutical Medicine. 2009,1534(1): 193-193.
[3] Begaud B. Glossary. Methodological approaches inpharmacoepidemiology [M].Amsterdam: ElsevierScience Publishers B.V.,1993:157-171.
[4] World Health Organization. The importance of pharmacovigilance-Safety monitoring of medical products[EB/OL]. (2002-10)[2017-01-11].http://apps.who.int/iris/bitstream/10665/42493/1/a75646.pdf.
[5] WHO-UMC. Glossary of terms used in pharmocovigilance [EB/OL] .(2015-01)[2016-11-17].http://www.who-umc.org/graphics/28401.pdf.
[6] ICH Expert Working Group. ICHHarmonised tripartite guideline:clinical safety data management: definitions and standards for expedited reporting E2A[EB/OL]. (1994-10-27)[2016-11-17].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf.
[7] ICH Expert Working Group. ICH Harmonised tripartite guideline:Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports E2B(R3)[eb/ol].(2005-05)[2016-11-17].http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html.
[8] ICH Expert Working Group.ICH Harmonised tripartite guideline:periodic benefit-risk evaluation report (PBRER)E2C(R2) [EB/OL]. (2012-12-17) [2016-11-17].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2C/E2C_R2_Step4.pdf.
[9] ICH Expert Working Group. ICH Harmonised tripartite guideline:post-approval safety data management: definitions and standards for expedited reporting E2D[EB/OL]. (2003-11-12)[2016-11-17].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf.
[10] ICH Expert Working Group.ICHHarmonised tripartite guideline:pharmacovigilance planning E2E[EB/OL]. (2012-12-17)[2016-11-17].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2C/E2C_R2_Step4.pdf.
[11] 董铎,吴桂枝,程刚. 欧盟新法规下的药物警戒制度简介[J].中国药物警戒,2012, 9(11):662-665.
[12] Bush J K, Dai W S, Dieck G S, et al. The art and science of risk management: a US research-based industry perspective[J]. Drug Safety, 2005, 28(1):1-18.
[13] 中华人民共和国卫生部. 药品生产质量管理规范（第79号令）[EB/OL]. (2011-01-17)[2017-02-08].http://www.sfda.gov.cn/WS01/CL0053/58500.html.
[14] 中华人民共和国卫生部. 药品不良反应报告和监测管理办法（第81号令）[EB/OL]. (2011-05-04) [2017-02-08].http://www.sda.gov.cn/WS01/CL0053/62621.html.
[15] The European Medicines Agency. EMA pharmacovigilance system manual Version 1.2.[EB/OL]. (2016-10-13)[2017-02-08].http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/07/WC500170226.pdf.